FDAnews
www.fdanews.com/articles/202791-aadi-bioscience-to-acquire-aerpio-and-develop-cancer-drug-fyarro

Aadi Bioscience to Acquire Aerpio and Develop Cancer Drug Fyarro

May 18, 2021

California drugmaker Aadi Biosience is acquiring Ohio-based Aerpio Pharmaceuticals and the combined companies plan to focus on developing Aadi’s experimental cancer drug, Fyarro (sirolimus albumin-bound nanoparticles).

Fyarro is being developed to treat advanced malignant perivascular epithelioid cell tumors and solid tumors containing alterations in the TSC1 and TSC2 genes.

The drug has already secured Orphan Drug, Fast-Track and Breakthrough Therapy designations from the FDA, and the companies plan to launch further clinical trials late this year.

View today's stories